Pfizer Inc. (PFE)
| Previous Close | 41.32 |
| Open | 41.60 |
| Bid | 42.13 x 1800 |
| Ask | 42.14 x 1200 |
| Day's Range | 41.59 - 42.19 |
| 52 Week Range | 32.83 - 51.86 |
| Volume | 8,777,359 |
| Avg. Volume | 32,794,835 |
| Market Cap | 235.927B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 21.35 |
| EPS (TTM) | 1.97 |
| Earnings Date | Oct. 25, 2021 - Oct. 29, 2021 |
| Forward Dividend & Yield | 1.56 (3.98%) |
| Ex-Dividend Date | Jul. 29, 2021 |
| 1y Target Est | 46.23 |
- Editor's PickYahoo Finance Video
How Johnson & Johnson’s vaccine meets the ‘gold standard’ of the WHO
Johnson & Johnson CFO Joseph J. Wolk joins Yahoo Finance to discuss Johnson & Johnson’s recent earnings, the effectiveness of its vaccine, and the importance of innovation.
- Simply Wall St.
What Kind Of Shareholders Own Pfizer Inc. (NYSE:PFE)?
If you want to know who really controls Pfizer Inc. ( NYSE:PFE ), then you'll have to look at the makeup of its share...
- Motley Fool
Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine
While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.
